Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Inc.

www.amgen.com

Latest From Amgen Inc.

Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.

ImmunoOncology Deals

Why The M&A Boom Many Expected In 2018 Didn’t Happen

High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.

M & A Outlook 2019

Why The M&A Boom Many Expected In 2018 Didn’t Happen

High valuations, an uncertain biopharma macro environment and widespread use of US tax reform benefits for share buybacks and capital investments resulted in less major M&A than expected. Opinions vary widely on whether 2019 will be any different.

M & A Outlook 2019

The Harsh Light Of Hard Facts: Valuing Pharma In A Made For Measure World

With a challenging new decade of scientific discovery looming, 2019 is the positioning year for biopharma to make value, transparency, information and culture work seamlessly to achieve innovations that matter to patients, payers and society.

Commercial Market Intelligence
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register